NCT05282498 (MYOVAx) is a clinical trial in Myocarditis, sponsored by National Heart Centre Singapore.

Who is sponsoring NCT05282498?

NCT05282498 is sponsored by National Heart Centre Singapore.

What condition does NCT05282498 study?

NCT05282498 studies Myocarditis.

Is NCT05282498 still recruiting?

NCT05282498 is currently status unknown. Last updated 13 April 2022.

Last reviewed 2022-04-13 · How we verify

NCT05282498: MYOVAx

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Pathophysiologic Mechanism for MYOcarditis in COVID19 VAccinations ("MYOVAx" Study)

Status unknown Last updated 13 April 2022

What this trial tests

trial in Myocarditis in 50 participants. Status unknown.

Timeline

1 November 2021

Primary endpoint
30 September 2023

31 December 2023

Quick facts

Lead sponsor	National Heart Centre Singapore
Status	Status unknown
Study type	OBSERVATIONAL
Enrollment	50
Start date	1 November 2021
Primary completion	30 September 2023
Estimated completion	31 December 2023
Sites	1 location across Singapore

Conditions studied

Myocarditis — all drugs for Myocarditis →

Sponsor

National Heart Centre Singapore — full company profile →

Who can join

Adults 5 to 99, any sex, with Myocarditis. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The coronavirus disease 2019 (COVID-19) is an ongoing pandemic which has infected more than 160 million people and caused 3.4 million deaths worldwide till May 2021. With the recent rollout of COVID-19 vaccines globally and in Singapore, reports of rare but serious cardiovascular-related side effects started to appear. Although a link between adenovirus-based vaccines (AstraZeneca ChAdOx1 and J\&J Ad26.COV2.S) and cerebral venous sinus thrombosis (CVST) and immune thrombocytopenia has been widely reported, these vaccines are current not in use in Singapore. Yet, acute myocarditis and other cardiovascular symptoms has also been observed to be associated with the two mRNA-based vaccines (Pfizer-BioNTech BNT162b2 and Moderna mRNA-1273) in-use in Singapore. In Singapore acute myocarditis is of particular concern with at least 12 cases reported by the Health Services Authority (HSA). The US FDA and EU authorities have confirmed there to be an association between the mRNA vaccines and myocarditis.The study aims to (1) To study possible mechanisms of COVID-19 vaccines in causing myocarditis in patients with confirmed vaccine-associated myocarditis (2) To risk stratify for vaccine-associated myocarditis in the at-risk population of young men (3) To identify potential preventative strategies to mitigate vaccine-associated myocarditis in high-risk individuals

Publications & conference data

2 peer-reviewed publications reference this trial (live from Europe PMC):

From bench to bedside: Unveiling the background and benefits of nanovaccines tested in clinics.
Egorova VS, Kolesova EP, Voronina MV, Denisova ER, et al · · 2026 · PMID 41810466 · DOI 10.1016/j.ajps.2026.101116
Epidemiology of Myocarditis in Young and Middle-Aged Population in Asia.
Li C, Lu Z, Wang DW. · · 2025 · PMID 41198371 · DOI 10.1016/j.jacasi.2025.08.027

Verify or expand the search:

Other recruiting trials for Myocarditis

Currently open trials in the same condition.

NCT06889662 — GEAM Study Aims At Assessing the Role of Genetic Testing in Patients with Arrhythmic Myocarditis. · recruiting
NCT06730607 — Image-Based Prediction of Ventricular Tachycardias in Post-Myocarditis Patients: an International Multicenter Case-contr · recruiting
NCT06566209 — FDG-PET as an Imaging Modality to Diagnose and Risk Stratify Subclinical, Imaging Negative Ici-Myocarditis · recruiting
NCT07086144 — Efficacy of a Myocardial Panel in the Management and Treatment of Pediatric Myocarditis · NA · recruiting
NCT06158698 — CMP-MYTHiC Trial and Registry - CardioMyoPathy With MYocarditis THerapy With Colchicine · Phase 3 · recruiting

Other National Heart Centre Singapore trials

Trials by the same sponsor.

NCT06645691 — Hyperpolarized MR Imaging with Carbon-13 Pyruvate in the Human Body · Phase 2 · recruiting
NCT05912218 — REducing Diabetic MacrovascUlar Complications DuE to Peripheral Arterial Disease- REDUCE-PAD · Phase 2 · active not recruiting
NCT05946174 — Tackling Disruptions to Frailty Interventions: Developing Personalized Interventions Targeted for Older Persons With Car · NA · recruiting
NCT05775484 — Exercise to Slow Cardiovascular Ageing Progression · recruiting
NCT07376993 — Pulse Signal Acquisition in Patients With Heart Failure · NA · active not recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT05282498 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by National Heart Centre Singapore
Last refreshed: 13 April 2022

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05282498.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing